NASDAQ:TERN Terns Pharmaceuticals - TERN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.94 -0.13 (-1.43%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.73▼$9.2350-Day Range$5.53▼$10.1852-Week Range$1.45▼$10.67Volume308,591 shsAverage Volume141,640 shsMarket Capitalization$336.23 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Terns Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside0.7% Upside$9.00 Price TargetShort InterestHealthy3.87% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment1.43Based on 2 Articles This WeekInsider TradingSelling Shares$8.25 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.91) to ($1.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector484th out of 1,053 stocksPharmaceutical Preparations Industry245th out of 519 stocks 1.2 Analyst's Opinion Consensus RatingTerns Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Terns Pharmaceuticals has a forecasted upside of 0.7% from its current price of $8.94.Amount of Analyst CoverageTerns Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.87% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 14.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTerns Pharmaceuticals has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Terns Pharmaceuticals is -0.84. Previous Next 3.6 News and Social Media Coverage News SentimentTerns Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Terns Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold 26.92% more of their company's stock than they have bought. Specifically, they have bought $6,499,995.00 in company stock and sold $8,250,000.00 in company stock.Percentage Held by Insiders21.00% of the stock of Terns Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Terns Pharmaceuticals are expected to grow in the coming year, from ($1.91) to ($1.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -4.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Terns Pharmaceuticals (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Read More Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TERN Stock News HeadlinesJanuary 12, 2023 | finance.yahoo.comTerns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology ConferenceJanuary 5, 2023 | finance.yahoo.comTerns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare ConferenceFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 23, 2022 | finance.yahoo.comTerns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesDecember 21, 2022 | msn.comTerns Pharmaceuticals, OceanPal among premarket losers' packDecember 21, 2022 | msn.comTerns Pharmaceuticals slumps 7.7% on pricing $75M offeringDecember 20, 2022 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)December 19, 2022 | finance.yahoo.comTerns Announces Proposed Public OfferingFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 19, 2022 | msn.comTELL, ICPT and VKTX among mid-day moversDecember 1, 2022 | finance.yahoo.comTerns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology SummitNovember 16, 2022 | finance.yahoo.comWe're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn RateNovember 9, 2022 | finance.yahoo.comTerns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate HighlightsNovember 4, 2022 | finance.yahoo.comTerns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022October 26, 2022 | finance.yahoo.comTerns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022October 12, 2022 | finance.yahoo.comZacks.com featured highlights include Terns Pharmaceuticals, AllianceBernstein Holding and ALLETEOctober 11, 2022 | finance.yahoo.comTerns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor ConferenceOctober 11, 2022 | msn.com3 Stocks for Higher Returns as New Analysts Initiate CoverageSeptember 20, 2022 | finance.yahoo.comNew Analysts Initiate Coverage: 3 Top-Ranked Stocks to BuySeptember 20, 2022 | finance.yahoo.comNew Analysts Initiate Coverage: 3 Top-Ranked Stocks to BuySeptember 12, 2022 | finance.yahoo.comAnalyst Outlines Doubts On This NASH-Focused Stock, Builds Neutral CaseSeptember 9, 2022 | msn.com$2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are BuyingAugust 19, 2022 | finance.yahoo.comTerns Pharmaceuticals, Inc.'s (NASDAQ:TERN) market cap surged US$112m last week, individual investors who have a lot riding on the company were rewardedAugust 17, 2022 | nasdaq.comWednesday 8/17 Insider Buying Report: TERN, KDPAugust 12, 2022 | msn.comU.S. Stocks Trade Higher; Consumer Sentiment Tops EstimatesJuly 27, 2022 | finance.yahoo.comTerns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of DirectorsJuly 22, 2022 | finance.yahoo.comAll You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to BuySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TERN Company Calendar Last Earnings11/09/2022Today2/02/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TERN CUSIPN/A CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+0.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,160,000.00 Net MarginsN/A Pretax Margin-5,829.60% Return on Equity-37.32% Return on Assets-35.50% Debt Debt-to-Equity RatioN/A Current Ratio25.47 Quick Ratio25.47 Sales & Book Value Annual Sales$1 million Price / Sales336.23 Cash FlowN/A Price / Cash FlowN/A Book Value$6.34 per share Price / Book1.41Miscellaneous Outstanding Shares37,610,000Free Float29,715,000Market Cap$336.23 million OptionableNot Optionable Beta-1.01 Key ExecutivesMr. Senthil Vel Sundaram (Age 44)CEO & Director Comp: $850.2kDr. Erin Quirk M.D. (Age 51)Pres & Head of R&D Comp: $662.55kMr. Seokho Yoon Esq. (Age 44)COO, Gen. Counsel & Sec. Comp: $609.37kDr. Weidong Zhong Ph.D. (Age 56)Co-Founder & Exec. Officer Dr. Mark Joseph Vignola (Age 44)CFO & Treasurer Dr. Jeffrey R. Jasper Ph.D.Sr. VP & Head of ResearchMs. Diana ChungSr. VP & Chief Devel. OfficerDr. Kerry Russell M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsKinnate BiopharmaNASDAQ:KNTEAcrivon TherapeuticsNASDAQ:ACRVAnnexonNASDAQ:ANNXOrganogenesisNASDAQ:ORGOG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInsiders & InstitutionsBank of Montreal CanBought 194,100 shares on 2/1/2023Ownership: 0.516%Zurcher Kantonalbank Zurich Cantonalbank Bought 5,050 shares on 2/1/2023Ownership: 0.013%Orbimed Advisors LlcBought 137,931 shares on 12/23/2022Total: $999,999.75 ($7.25/share)Vivo Opportunity, LlcBought 758,620 shares on 12/23/2022Total: $5.50 M ($7.25/share)Biosciences Fund V L.P. LavSold 1,500,000 sharesTotal: $8.25 M ($5.50/share)View All Insider TransactionsView All Institutional Transactions TERN Stock - Frequently Asked Questions Should I buy or sell Terns Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TERN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TERN, but not buy additional shares or sell existing shares. View TERN analyst ratings or view top-rated stocks. What is Terns Pharmaceuticals' stock price forecast for 2023? 3 equities research analysts have issued 1-year target prices for Terns Pharmaceuticals' stock. Their TERN share price forecasts range from $6.00 to $14.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 0.7% from the stock's current price. View analysts price targets for TERN or view top-rated stocks among Wall Street analysts. How have TERN shares performed in 2023? Terns Pharmaceuticals' stock was trading at $10.18 at the beginning of 2023. Since then, TERN shares have decreased by 12.2% and is now trading at $8.94. View the best growth stocks for 2023 here. When is Terns Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our TERN earnings forecast. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) posted its quarterly earnings results on Wednesday, November, 9th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.07. When did Terns Pharmaceuticals IPO? (TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO. What is Terns Pharmaceuticals' stock symbol? Terns Pharmaceuticals trades on the NASDAQ under the ticker symbol "TERN." Who are Terns Pharmaceuticals' major shareholders? Terns Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.52%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Insiders that own company stock include Biosciences Fund V LP Lav, Hongbo Lu, James E Flynn, Orbimed Advisors Llc, Vivo Capital Fund Viii, LP and Vivo Opportunity, Llc. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Terns Pharmaceuticals' stock price today? One share of TERN stock can currently be purchased for approximately $8.94. How much money does Terns Pharmaceuticals make? Terns Pharmaceuticals (NASDAQ:TERN) has a market capitalization of $336.23 million and generates $1 million in revenue each year. The company earns $-50,160,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. How can I contact Terns Pharmaceuticals? Terns Pharmaceuticals' mailing address is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. The official website for the company is www.ternspharma.com. The company can be reached via phone at 650-525-5535 or via email at investors@ternspharma.com. This page (NASDAQ:TERN) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.